Atezolizumab in Combination With Carboplatin and Nab-Paclitaxel in Advanced Squamous NSCLC (IMpower131): Results From a Randomized Phase III Trial
Robert M. Jotte, Federico Cappuzzo, Ihor Vynnychenko, Daniil Stroyakovskiy, Delvys Rodríguez‐Abreu, Maen Hussein, Ross A. Soo, Henry Jacob Conter, Toshiyuki Kozuki, Kuan-Chieh Huang, Vilma Graupner, Shawn W. Sun, Tien Hoang, Helen Jessop, Mark L. McCleland, Marcus Ballinger, Alan Sandler, Mark A. Socinski
Journal of Thoracic Oncology, 2020
Abstract
This research paper explore the methodology and findings associated with Journal of Thoracic Oncology. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).
- Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer 2016
- Cell-cycle dependent antagonistic interactions between paclitaxel and carboplatin in combination therapy 2007
- First-Line Atezolizumab Effective in Bladder Cancer 2016
- Immunotherapy-related hepatitis and thrombocytopaenia induced by the very low dose of only 90 mg of atezolizumab 2020
- Pharmacokinetics of paclitaxel and carboplatin in combination. 1995
- The American Joint Committee on Cancer: the 7th Edition of the AJCC Cancer Staging Manual and the Future of TNM 2010
- Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial 2016
- Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial 2016
- Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up 2016
- Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance 2013